1. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025)
- Author
-
Rozenn Brillet, Margot Morin-Dewaele, Patrice Bruscella, Nazim Ahnou, Jean-Michel Pawlotsky, Abdelhakim Ahmed-Belkacem, François Berry, Laurent Softic, Slim Fourati, Sabah Hamadat, Quentin Nevers, Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18) (Inserm U955), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Henri Mondor, Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), and Bruscella, Patrice
- Subjects
Oncology ,medicine.medical_specialty ,Colorectal cancer ,viruses ,Pneumonia, Viral ,Population ,Single-nucleotide polymorphism ,Virus Replication ,Antiviral Agents ,Cell Line ,Betacoronavirus ,Cyclophilins ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Chlorocebus aethiops ,medicine ,Animals ,Humans ,Pharmacology (medical) ,Risk factor ,education ,Pandemics ,Vero Cells ,030304 developmental biology ,[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Pharmacology ,0303 health sciences ,education.field_of_study ,Alisporivir ,SARS-CoV-2 ,business.industry ,alisporivir ,virus diseases ,COVID-19 ,Microsatellite instability ,Cancer ,Odds ratio ,medicine.disease ,antiviral ,3. Good health ,Infectious Diseases ,030220 oncology & carcinogenesis ,cyclophilin ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Cyclosporine ,Coronavirus Infections ,business - Abstract
Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC50) of 0.46 ± 0.04 μM. Alisporivir inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 infection.
- Published
- 2020
- Full Text
- View/download PDF